PEDIATRICS Vol. 90 No. 6 December 1992, pp. 920-923
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schuh, S.
Right arrow Articles by Jaffe, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schuh, S.
Right arrow Articles by Jaffe, D.

Efficacy of Adding Nebulized Ipratropium Bromide to Nebulized Albuterol Therapy in Acute Bronchiolitis

S. Schuh MD, FRCP(C)1, D. Johnson MD2, G. Canny MD, FRCP(C)3, J. Reisman MD, FRCP(C)3, M. Shields MD3, T. Kovesi MD, FRCP(C)3, E. Kerem MD3, L. Bentur MD3, H. Levison MD, FRCP(C)3, and D. Jaffe MD1

1 From the Department of Pediatrics, Division of Emergency, Hospital for Sick Children, Toronto, Ontario, Canada
2 From the Department of Pediatrics, Division of Pharmacology, Chest, Hospital for Sick Children, Toronto, Ontario, Canada
3 From the Department of Pediatrics, Division of Chest, Hospital for Sick Children, Toronto, Ontario, Canada

Nebulized ipratropium bromide is thought to be synergistic with albuterol in therapy for acute childhood asthma. Because the efficacy of ipratropium in bronchiolitis is uncertain and some infants with bronchiolitis do not respond to nebulized albuterol alone, the following study was undertaken. In this double-blind, placebo-controlled trial, 69 infants between 6 weeks and 24 months of age who exhibited the first episode of acute bronchiolitis were randomly assigned to receive either nebulized albuterol (0.15 mg/kg per dose) and ipratropium bromide (250 µg per dose) (group A, n = 36) or nebulized albuterol and normal saline (placebo) (group B, n = 33) for two doses, 1 hour apart. The two groups were comparable at baseline. Both therapies resulted in clinically significant improvement. However, the addition of ipratropium resulted in no additional benefit with respect to decrease in the respiratory rate (mean darr 10.6/min vs darr 8.6/min, P = .86), accessory muscle score (range 0 through 3) (darr 0.92 vs darr 0.82, z = –0.44), wheeze score (range 0 through 3) (darr, 0.94 vs 0.85, z –0.20), oxygen saturation (uarr 0.25% vs uarr –0.33%, P = .86), or hospitalization rate (17 vs 10). The number of "nonresponders" and "clear responders" was also very similar in both groups. No toxicity was noted. The increase in heart rate was mild and similar in both groups (uarr 6.7 vs uarr 11.1). The power of the study to detect a difference between the two treatment groups in the respiratory rate change ge 8/min is greater than 90%. It is concluded that the addition of nebulized ipratropium bromide appears to offer no further clinical benefit compared with albuterol alone in moderately severe acute bronchiolitis.

Key Words: bronchiolitis • ipratropium • albuterol

Submitted on March 10, 1992
Accepted on June 18, 1992




This article has been cited by other articles:


Home page
 Arch Pediatr Adolesc MedHome page
V. J. King, M. Viswanathan, W. C. Bordley, A. M. Jackman, S. F. Sutton, K. N. Lohr, and T. S. Carey
Pharmacologic Treatment of Bronchiolitis in Infants and Children: A Systematic Review
Arch Pediatr Adolesc Med, February 1, 2004; 158(2): 127 - 137.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. Zhang, C. Yu, S.T. Holgate, and T.F. Reiss
Variability and lack of predictive ability of asthma end-points in clinical trials
Eur. Respir. J., November 1, 2002; 20(5): 1102 - 1109.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. H. NUMA, G. D. WILLIAMS, and C. J. DAKIN
The Effect of Nebulized Epinephrine on Respiratory Mechanics and Gas Exchange in Bronchiolitis
Am. J. Respir. Crit. Care Med., July 1, 2001; 164(1): 86 - 91.
[Abstract] [Full Text] [PDF]